RE:RE:RE:RE:RE:RE:RE:Incentives to have a 1st cohort (UHN) 3-month data publishSkys1 ... "Current evaluation is a joke" ... I can understand that. But for how long?
Past is no more important. There's nothing you can do. But we now know that we have cancer-free patient from Ph. 1b, that things are moving ahead regarding Ph. 2b, no matter how slow that can be for one's perception.
But what's more important to you? That the stock price would have skyrocketed 3 years ago on hype and that you couldn't have accumulated enough or that it's been an opportunity for you to accumulate to a level that will make a huge difference in your life?
At least, your downside is minimal, not to say null, considering all the clinical data we now know.. And your upside simply spectacular on additional data in line with Ph. 1b. Would have wanted to enter at much higher price and then see a pullback of 90% like Bunge's PMN stock?
It's your investment decision. You do whatever you feel is best for you.